


- ozogamicin reduces relapse risk in FLT3/ITD acute myeloid leukemia: a report from the Children's Oncology Group[J]. Clin Cancer Res, 2016, 22(8): 1951-1957.
- [34] Olombel G, Guerin E, Guy J, et al. The level of blast CD33 expression positively impacts the effect of gemtuzumab ozogamicin in patients with acute myeloid leukemia[J]. Blood, 2016, 127(17): 2157-2160.
- [35] Pollard JA, Loken M, Gerbing RB, et al. CD33 expression and its association with gemtuzumab ozogamicin response: results from the randomized phase III Children's Oncology Group trial AAML0531[J]. J Clin Oncol, 2016, 34(7): 747-755.
- [36] Rashidi A, Walter RB. Antigen-specific immunotherapy for acute myeloid leukemia: where are we now, and where do we go from here[J]. Exp Rev Hematol, 2016, 9(4): 335-350.
- [37] Reusch U, Harrington KH, Gudgeon CJ, et al. Characterization of CD33/CD3 tetraivalent bispecific tandem diabodies (TandAbs) for the treatment of acute myeloid leukemia[J]. Clin Cancer Res, 2016, 22(23): 5829-5838.
- [38] Harrington KH, Gudgeon CJ, Laszlo GS, et al. The broad anti-AML activity of the CD33/CD3 BiTE antibody construct, AMG 330, is impacted by disease stage and risk[J]. PLoS One, 2015, 10(8): e135945.
- [39] Al-Hussaini M, Rettig MP, Ritchey JK, et al. Targeting CD123 in acute myeloid leukemia using a T-cell-directed dual-affinity retargeting platform[J]. Blood, 2016, 127(1): 122-131.
- [40] Chien CD, Sauter CT, Ishii K, et al. Preclinical development of FLT3-redirected chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia[J]. Blood, 2016, 128(22): 1072.
- [41] Krupka C, Kufer P, Kischel R, et al. Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism[J]. Leukemia, 2016, 30(2): 484-491.
- [42] Wei A, Tan P, Perruzza S, et al. Maintenance lenalidomide in combination with 5-azacitidine as post-remission therapy for acute myeloid leukaemia[J]. Br J Haematol, 2015, 169(2): 199-210.
- [43] Turtle CJ, Hanafi LA, Berger C, et al. CD19 CAR-T cells of defined CD4⁺: CD8⁺ composition in adult B cell ALL patients[J]. J Clin Invest, 2016, 126(6): 2123-2138.

(本文编辑: 俞燕)

· 消息 ·

《实用儿童脑病学》新书介绍



儿童脑损伤和脑病是危害儿童健康成长和人口素质的主要疾病,严重影响儿童社会交往能力、适应能力、注意力和学习能力,甚至导致癫痫、视听障碍、语言障碍、智力障碍、脑性瘫痪、植物状态等神经伤残。

由陈光福教授主编、人民卫生出版社出版的《实用儿童脑病学》,全书共30章,139万字,460多幅图(部分彩图),涉及儿童神经发育、神经解剖、神经影像学检查、脑功能检查、神经学检查评估、神经保护治疗、神经免疫治疗、神经修复治疗与康复治疗,以及各种儿童脑疾病的病因、发病机制、病理、临床表现、诊断方法与治疗进展等内容。

本书编委为从事儿童神经发育基础、神经影像、神经电生理、神经内科、神经外科、儿童康复和新生儿等专业的专家,专家们历时2年精心撰写,反复修改、补充,力求反映本领域近5年国内外的最新研究进展、诊治指南和专家共识,以及作者的临床经验与研究成果,并对新的探索性治疗应用前景进行了述评和展望。全书图文并茂、条理清晰、内容丰富、可读性强,是一部具有先进性、科学性和实用性的专业参考书。

有意购买者请联系王波医师,电话:13823108103,邮箱:66286432@qq.com。